At a glance
ClinicalIndex Comparison Record- ✓HIV-1 infection documented for more than 365 days ago
- ✓Viral suppression to ≤50 copies/mL for at least 48 weeks
- ✓CD4 count >250 cells/µL at enrollment
- ✓Age 18–65 years
- ✕History of allergic reaction to proposed vaccines or egg allergy
- ✕History of Guillain-Barré syndrome
- ✕Currently receiving immunosuppressive medications
- ✕Pregnancy or lactation
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Perturbing the HIV Reservoir With Immune Stimulation
In Brief
A clinical study evaluating Fluarix, Pneumovax, and 1 other intervention for AIDS and HIV. Completed, enrolled 54 participants across 1 site.
Detailed Summary
The purpose of this study is to determine the impact of Pneumococcus and Influenza vaccines on the HIV transcriptional activity in individuals who are virologically suppressed for at least 48 weeks on similar ART. The proposed study is a randomized double-blinded control trial conducted over 28 weeks. Randomized interventions will be injections of Influenza vaccine, Pneumococcal vaccine, and Placebo. Each participant will receive each injection but in a randomized order.
Study Details
Timeline
Interventions
Intramuscular injection with Fluarix® .
Intramuscular injection with Pneumovax.
Intramuscular injection with sterile saline (placebo).